Contribute Try STAT+ Today

Gilead’s research and development chief is stepping down after nearly three decades at the company, concluding a run in which he steered the development of pioneering blockbuster therapies for HIV and hepatitis C but more recently became the target of Wall Street ire amid Gilead’s struggles to find a third act.

Norbert Bischofberger will leave his post at the end of April but will stay with the company through July, Gilead (GILD) announced on Monday. The company did not give a reason for his departure, but the move offers Gilead a chance to freshen its uppermost ranks without shaking up its strategy.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Your daily dose of news in health and medicine

Privacy Policy